Full Service Test Menu

Diagnostic, prognostic, predictive and predisposition testing for oncology and pathology
Comprehensive cancer testing from one dynamic laboratory

Offering a full continuum with standard-of-care, innovative, customized and clinical research options

NeoGenomics has served the oncology and pathology communities for over 20 years.

NeoGenomics has a unique depth of service in hematologic and solid tumor cancer diagnostics with over 500 available tests. Our dedication to patient care and customer service guides our commitment to innovate better cancer laboratory services.

NeoGenomics is the premier laboratory of choice for large and small pathology practices, community oncology centers, academic medical centers and clinical researchers. Some of the advantages of working with NeoGenomics are:

- **Multimodality test methods** offered in-house allows for maximizing yield from small specimens and reduces turnaround time, increasing efficiency for clients.

- **Extremely rapid development cycle** enables us to respond quickly to changes in guidelines and newly-published findings.

- **Most comprehensive molecular oncology menu** available with broad-coverage and targeted tumor profiles, liquid biopsy assays, panels, single-gene biomarkers and hereditary cancer testing.

- **Pharma Services** division supports clinical research and biomarker development around the world with a wide range of service offerings, dedicated project staff and facility space.

NeoGenomics is committed to the highest level of service to patients and clients.

We look forward to working with you to enhance your practice, create testing solutions and improve patient care.
Molecular

Hematologic cancer panels and profiles

- Neo Comprehensive™ — Heme Cancers (433 genes)
- Neo Comprehensive™ — Myeloid Disorders (164 genes)
- NeoTYPE® Cancer Profiles
  - AITL/Peripheral T-Cell Lymphoma
  - ALL
  - AML Prognostic
  - CLL
  - Follicular Lymphoma
  - Lymphoid Disorders (128 genes)
  - Lymphoma
  - MDS/CMML
- BTK Inhibitor Acquired Resistance Panel
- MPN JAK2 V617F with Sequential Reflex to JAK2 Exon 12-13, CALR, and MPL
- Rapid AML Therapeutic Panel

Solid tumor cancer panels and profiles

- Neo Comprehensive™ — Solid Tumor (517 genes)
- NeoTYPE® DNA & RNA — Brain
- NeoTYPE® DNA & RNA — Lung
- NeoTYPE® Cancer Profiles (with Tumor Mutation Burden)
  - Breast
  - Cervical
  - Cholangiocarcinoma
  - Colorectal
  - Discovery (336 biomarkers)
  - Endometrial
  - Esophageal
  - Gastric
  - GI Predictive
  - GIST and Soft Tissue Tumor
  - Head and Neck
  - HRR (no TMB)
  - Liposarcoma Fusion (no TMB)
  - Liver/Biliary
  - Lung, DNA & RNA
  - Melanoma
  - Other Solid Tumor
  - Ovarian
  - Pancreas
  - Precision (83 biomarkers)
  - Thyroid
- NGS Fusion Panels
  - Brain
  - Breast
  - Cholangio/Pancreatic Carcinoma
  - Colorectal
  - Ewing Sarcoma
  - Lung
  - Non-Ewing Sarcoma
  - NTRK
  - NTRK and RET
  - Prostate
  - Rhabdomyosarcoma
  - Salivary Gland
  - Sarcoma Comprehensive
  - Targeted Solid Tumor
  - Thyroid
  - Universal Solid Tumor
- BRCA1/2 for Tumors
- Breast Cancer Index® (BCI)*
- CancerTYPE ID® *
- Early-stage NSCLC Panel
- HPV DNA Tissue Testing
- Microsatellite Instability
- RAS/RAF Panel
*Performed by Biotheranostics, Inc.

Solid tumor liquid biopsies

- InVisionFirst®—Lung
- NeoLAB® Solid Tumor

Hereditary cancer predisposition

Note: These tests are send-outs.

- Bone Marrow Failure NGS Panel
- BRCA1 Single Gene
- BRCA2 Single Gene
- BRCA1 and BRCA2 Focus Panel
- Colorectal Cancer Focus Panel
- Comprehensive Cancer Panel
- Focus Cancer Panel

Single gene tests

- ABL1 Kinase Domain
- ALK Mutation Analysis
- B-Cell Gene Rearrangement
- BCR-ABL1, t(9;22) (p210, p190) (p230)
- BRAF
- CALR
- CEBPA
- CSF3R
- CXCR4
- EGFR
- FLT3
- IDH1/IDH2
- IgH Clonality by NGS
- IgVH
- inv(16), CBFB-MYH11
- JAK2 V617F
- JAK2 Exon 12-13
- KIT
- KRAS
- MET (c-MET)
- MET exon 14 Deletion Analysis
- MGMT Methylation
- MLH1 Methylation
- MPL
- MYD88
- NOTCH1
- NPM1
- NPM1 MRD Analysis
- NRAS
- PDGFRα
- PIK3CA
- PML-RARA, t(15;17)
- PTEN
- RUNX1-RUNX1T1 (AML1-ETO), t(8;21)
- T-Cell Receptor Beta
- T-Cell Receptor Gamma
- TERT Promoter Mutation Analysis
- TP53

NeoGenomics Laboratories — 3
### Consultations
- Cancer of Unknown Primary
- Hematologic Cancers
- Molar Pregnancy
- Solid Tumors

### Cytogenetics
- Oncology Chromosome Analysis
  - Hematologic Cancers

### FISH

#### HemeFISH®
- Acute Lymphoblastic Leukemia (ALL)
  - ALL Panel
  - ALL Profile (Ph-Like)
  - CDKN2A/B (p16) Deletion
- Acute Myeloid Leukemia (AML)
  - AML Standard Panel
  - AML Favorable-Risk Panel
  - AML Non-Favorable Risk Panel
  - NUP98
- BCR/ABL1/ASS1
- CLL Panel
- Lymphoma
  - ALCL Panel
  - BCL6/MYC t(3;8)
  - DUSP22-IRF4 Rearrangement
  - High-Grade B-Cell Lymphoma Reflex Panel
  - High-Grade/Large B-Cell Lymphoma Panel
  - IGK/MYC t(2;8)
  - IGL/MYC t(8;22)
  - Low-Grade/Small B-Cell Lymphoma Panel
  - NHL Panel
  - TCL1
  - TP63 Rearrangement
  - 11q Aberration in NHL
  - 1p36 Deletion
- Myelodysplastic Syndrome (MDS)
  - MDS Extended Panel
  - MDS Standard Panel
- Plasma Cell Myeloma
  - Plasma Cell Myeloma IgH Complex Panel
  - Plasma Cell Myeloma Panel
  - Plasma Cell Myeloma Prognostic Panel
- Myeloproliferative Neoplasm (MPN) and Eosinophilia
  - Eosinophilia Panel
- MPN Panel
- JAK2 (9p24.1)
- PML/RARA and RARA Break-Apart
- Comprehensive Menu of Individual Hematologic FISH Probes

#### FISH for solid tumors
- 1p/19q Deletion (Glioma)
- Bladder Cancer FISH
- BRAF Rearrangement (Brain and Others)
- CDKN2A/B (p16, Mesothelioma or Glioma)
- EGFR Amplification
- FGFR2 Rearrangement
- HER2
  - HER2 Breast
  - HER2 Gastric/GEA
  - HER2 (Other)
- Lung Cancer - NSCLC
  - ALK
  - RET
  - ROS1
- MDM2
- MET
- MYC Amplification (Angiosarcoma)
- MYCN Amplification
- NeoSITE® Melanoma
- NTRK1, NTRK2, NTRK3
- NTRK3 FISH
- PDGFB Rearrangement (DFSP)
- PDGFRα Amplification (Brain)
- Ploidy FISH for Molar Pregnancy
- PTEN (Prostate and Others)
- RET
- Sarcoma
  - DDIT3 (CHOP)
  - EWSR1
  - MDM2
  - SS18 (SYT)
- TFE3
- USP6
Flow Cytometry

- Standard Leukemia/Lymphoma Panel - 24 markers
- Extended Leukemia/Lymphoma Panel - 31 markers
- CD4/CD8 Ratio for BAL
- Add-On Tubes
  - AML
  - B-ALL
  - CLL/Mantle Cell Companion
  - Erythroid-Mega
  - Hairy Cell
  - Mast Cell
  - Plasma Cell
  - T-ALL
  - TRBC1/LGL
- Follow-up Panels
  - AML
  - B-ALL
  - Hairy Cell
  - Plasma Cell
  - T-ALL
- MRD Panels
  - B-ALL MRD Panel
  - CLL MRD Panel
  - MM MRD Panel
- PNH High Sensitivity Evaluation
- T&B Tissue Panel
- TRBC1/T-Cell Lymphoma Companion Panel

Histology

Digital Image Analysis

*Notates tests that can be performed with digital image analysis

In Situ Hybridization (ISH)

- Albumin RNA ISH
- CMV ISH
- EBER
- HPV RNA ISH Panel
- Kappa/Lambda

Special stains

- AFB
- Alcian Blue
- Calcium Stain
- Colloidal Iron
- Congo Red
- Copper Stain
- Elastic Stain
- Fite Stain
- Fontana Masson
- GMS
- Gram Stain
- Iron
- Mucicarmine
- PAS
- PAS for Fungus
- PAS with Digestion
- Reticulin
- Trichrome
- Wright Giemsa

Immunohistochemistry (IHC) antibodies

- AAT
- ACTH
- Adenovirus
- AFP
- ALK (D5F3)
- ALK-1 (heme)
- Amyloid A
- Amyloid P
- Annexin A1
- AR*
- ATRX
- Ariginase 1
- B72.3
- BAP1
- BCL1/Cyclin D1
- BCL2
- BCL6
- BCL10
- BerEP4
- Beta Catenin
- BOB1
- BRAF V600E
- BRCA1
- Breast Triple Stain (CK5 + p63 + CK 8/18)
- BRG1 (SMARCA4)
- CA19.9
- Calcitonin
- Caldesmon
- Calponin
- Calretinin
Histology

Immunohistochemistry (IHC) antibodies, continued

- CAM 5.2 (CK LMW)
- Carbonic Anhydrase IX (CA IX)
- CD1a
- CD2
- CD3
- CD4
- CD5
- CD7
- CD8
- CD10
- CD11c
- CD14
- CD15
- CD19
- CD20
- CD21
- CD22
- CD23
- CD25
- CD30
- CD31
- CD33
- CD34
- CD35
- CD38
- CD42b
- CD43
- CD44
- CD45 (LCA)
- CD56
- CD57
- CD61
- CD68
- CD71
- CD79a
- CD99
- CD103
- CD117 cKIT
- CD123
- CD138
- CD163
- CDK4
- CDX2
- CDX2/CK7 Double Stain
- CEA (Mono)
- CEA (Poly)
- Chromogranin A
- LMO2
- Lysozyme
- MAL
- Mammaglobin
- MDM2
- Melan A (Mart1)
- Melan A/Ki67
- MITF
- MLH1*
- MOC31
- MPO
- MSA
- MSH2*
- MSH6*
- MUC1
- MUC2
- MUC4
- MUC5
- MUC6
- MUM1
- MyoD1
- Myogenin
- Napsin A
- NeuN
- NF (Neurofilament)
- NKKX2.2
- NKKX3.1
- NSE
- NUT
- OCT2
- OCT4
- Olig2
- p16
- p40
- p53
- p57
- p63
- p120 Catenin
- PS01S
- P504S
- pAKT
- Pan-Cytokeratin
- Pan-TRK
- Paraffin
- Parvovirus
- PAX2
- PAX5
- PAX8
- PD1
- PD-L1 22C3 FDA (KEYTRUDA®) for Cervical
- PD-L1 22C3 FDA (KEYTRUDA®) for Esophageal
- PD-L1 22C3 FDA (KEYTRUDA®) for Gastric/GEA
- PD-L1 22C3 FDA (KEYTRUDA®) for Head and Neck
- PD-L1 22C3 FDA for NSCLC
- PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast)
- PD-L1 SP142 FDA (TECENTRIQ®) for NSCLC
- PD-L1 28-8 FDA for NSCLC
- PD-L1 SP263 FDA for NSCLC
- PD-L1 28-8 (OPDIVO®) for Gastric/GEC
- PD-L1 LDT
- Perforin
- PgR*
- pHistone H3 (PHH3)
- PIT1
- PLAP
- PMS2*
- Pneumocystis Carinii (Jiroveci)
- PRAME
- Prolactin
- Prostate Triple Stain
- PSA
- PSAP/HPAP
- PSMA
- PTEN
- PTH
- RCC1
- Retinoblastoma Protein (RB)
- ROS1
- RRMI1
- S100
- S100p
- SALL4
- SATB2
- SF1
- SMA
- SMMHC
- Smoothelin
- Somatostatin Receptor, Type 2
- SOX2
- SOX10
- SOX11
- Spirochete
- STAT6
- Synaptophysin
- TCL1
- TCR BetaF1
- TCR Delta
- TdT
- TFE3
- Thymidylate Synthase (TS)
- Thrombomodulin (TM)
- Thyroglobulin (TGB)
- TIA1
- TLE1
- Toxoplasma
- TRAcP
- Trypsinase
- TSH
- TTF1
- Tuberculosis
- Tyrosinase
- Uroplakin II
- Uroplakin III
- Varicella Zoster Virus (VZV)
- Villin
- Vimentin
- WT1
NeoGenomics is the One Lab you can rely on for vital answers in cancer diagnostics throughout your patient’s entire cancer experience.

For more information, please connect with your Territory Business Manager, call Client Services at 866.776.5907 option 3, or visit our website at neogenomics.com.

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing, partnership opportunities and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry and immunohistochemistry through our nationwide network of CAP-accredited, CLIA-certified laboratories.